In recent years, 23andMe has repositioned itself as a genetic testing company that does more than help users fill out their family trees, but also answer crucial questions about their predispositions for potential conditions.
DiaMedica Therapeutics’ ReMEDy2 trial remains on clinical hold, with the FDA requesting more data to allay its concerns about how the potential stroke drug is administered intravenously.
There’s no shortage of recent studies showing that women are significantly less likely than men to receive the healthcare they need—due in large part to a lack of research and education around sex-based differences in therapies from both the pharma and medtech industries.
GSK has dumped one of its top pipeline prospects. While two of the three phase 3 trials of otilimab hit their primary endpoints, the Big Pharma concluded the efficacy fell short of the level needed to take the anti-GM-CSF antibody forward in rheumatoid arthritis (RA).
Seres Therapeutics’ SER-109 has faced more setbacks than most drugs, but the biotech has kept the faith and is now tantalizingly close to possibly seeing its candidate become the first FDA-approved oral microbiome therapeutic.
Clario, a clinical trial tech firm, has outlined three areas where artificial intelligence can improve patient experiences in the burgeoning landscape of decentralized clinical trials.
Merck KGaA, with phase 3 data on the horizon, showcases durability of evobrutinib in multiple sclerosis
Merck KGaA has provided efficacy data from the open-label extension of its phase 2 trial in relapsing multiple sclerosis, delivering evidence of the durability of the effects of the BTK inhibitor evobrutinib.
Pacific Biosciences raised the curtain on two DNA sequencers: its first short-read device, designed to offer new competition to the industry giant Illumina, as well as a machine poised to be an upgrade over its current long-read hardware.
In less than a week, Ipsen’s rare genetic disorder drug was set to go be reviewed by FDA’s independent expert panel, but that timeline is now off.
BOSTON—Artificial intelligence is often seen as a “black box,” a scary concept that becomes even more so as the technology becomes increasingly embedded in the healthcare industry.